Zacks Investment ResearchT3·8d ago
OGN Organon & Co.
XNYS
13.75
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
OGN
$13.75
—
Key stats
$13.75
- 52-Week Range
- $5.69 – $13.83
- YTD
- +89.92%
- IV Rank (30D)
- 27.19
- Straddle Price
- $11.20
- P/C Vol Ratio
- 0.32
- Market Cap
- $3.6B
- Open
- $13.75
- Day Range
- $13.74 – $13.76
- Volume
- 2,553,568
- Prev Close
- $13.75
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.88 |
| Cost of Equity (CAPM) | 9.56% (VRP-adj) |
| WACC | 6.56% |
| Volatility Risk Premium | +116.9pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -2.7% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $0.6B |
| Return on Equity (TTM) | 20.8% |
| Book / Price | 27.7% |
| Gross Margin (TTM) | 52.7% |
| FCF Margin (TTM) | 9.3% |
| Debt / Equity | 8.43 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | -1.6% (reverse-DCF on current price) |
| SMA 50 | $13.73 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $13.74 |
| Bollinger Width / SMA20 | 5.9% (drives anchor stability) |
| Net Debt | $7.3B |
| Market Cap | $4B |
Peers used for multiples: AMRX, CPRX, JNJ, LLY, MRK, PCRX, PEN, SUPN
Blended Fair Value
$34.31
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $10.84 | 23% | |
| DDM (Gordon) | $0.63 | 0% | |
| Peer P/E | $34.25 | 10% | median 43.9× · 7 peers |
| Peer EV/EBITDA | $109.72 | 10% | median 23.9× · 8 peers |
| Peer P/B | $29.97 | 2% | median 7.9× · 8 peers |
| Peer P/S | $138.02 | 7% | median 5.9× · 8 peers |
| Market Anchor (SMA50) | $13.73 | 47% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $13.43 | 0% | 7 strikes · skew -0.63 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $3.6B
- Employees
- 10,000
- List Date
- 2021-05-14
- CIK
- 0001821825
- Next Earnings
- 2026-11-09 (After-Close)
- EPS Forecast
- $0.95 (1 est.)
- Headquarters
- Jersey City, NJ
- Homepage
- https://www.organon.com
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | 2.41% | 7.34% | 13.19% | 4.01% | 17.96% | 8.98% |
| Feb | -- | 13.16% | -19.20% | 0.99% | 0.00% | -11.10% | -3.23% |
| Mar | -- | -6.75% | -3.17% | 7.06% | 3.76% | -16.69% | -3.16% |
| Apr | -- | -8.02% | 4.67% | 0.59% | -8.49% | 115.80% | 20.91% |
| May | -- | 18.33% | -20.86% | 13.28% | -2.43% | 0.38% | 1.74% |
| Jun | -18.22% | -10.60% | 6.99% | -3.18% | 4.65% | 1.35% | -3.17% |
| Jul | -5.87% | -7.39% | 6.85% | 7.63% | -3.48% | 0.00% | -0.38% |
| Aug | 14.76% | -10.37% | 1.06% | 3.23% | -3.38% | 1.47% | 1.13% |
| Sep | -5.12% | -18.78% | -21.59% | -13.36% | 13.38% | -0.44% | -7.65% |
| Oct | 10.26% | 8.77% | -11.38% | -0.27% | -38.58% | 0.29%* | -5.15% |
| Nov | -21.28% | -1.40% | -22.73% | -12.17% | 14.90% | -- | -8.54% |
| Dec | 5.99% | 5.72% | 25.39% | -4.17% | -5.66% | -- | 5.45% |
| Total | -22.89% | -19.62% | -45.89% | 9.10% | -29.01% | 94.33% | -2.33% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $13.75
SMA 50: $13.73
SMA 200: $11.35
Current: $13.75
EMA 12: $13.75
EMA 26: $13.74
MACD: 0.0140 | Signal: -0.0028
BULLISH
ADX (14): 23.45
WEAK TREND
+DI: 17.09
−DI: 11.24
Momentum Oscillators
RSI (14): 52.79
NEUTRAL
Stoch %K: 41.03
Stoch %D: 41.88
Williams %R: -61.54
Volume & Volatility
BB Upper: $13.80
BB Lower: $13.69
NEUTRAL
OBV: 255,109,382
Vol SMA 20: 2,233,609
Vol ROC: 22.18%
ATR: $0.04
True Range: $0.02
HV 20: 3.2%
HV 30: 2.8%
HV 60: 2.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-24T00:00:00 – 2026-10-22T00:00:00
AI Analysis
LLM Stock Analysis Report: OGN
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers and Primary Risks:
- Technical indicators suggest a potential reversal, with the RSI indicating overbought conditions.
- Options market signals are bearish, with a high put/call volume ratio and a low IV rank.
Investment Thesis: While OGN has experienced significant growth, its current price may be unsustainable given the overbought technical conditions. A pullback or correction is possible to retest support levels, providing an opportunity for traders to potentially enter long positions.
Recent News Sentiment Impact: The recent news headlines are mixed, but overall, they have a neutral impact on OGN's price movement. The positive sentiment from Sun Pharma's acquisition of Organon is tempered by the negative sentiment surrounding the company's earnings and regulatory issues.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bearish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bullish
Support/Resistance Levels: Key price levels to monitor are:
- Lower Bollinger Band: $5.63
- Middle MA (SMA 20): $10.36
- Upper Bollinger Band: $15.09
Momentum Signals:
- RSI interpretation: Overbought (>70)
- MACD signal: Bullish, but may be nearing a reversal
- Bollinger Bands position: Squeeze, indicating potential price movement
Volume Analysis: Volume trends and institutional interest signals are:
- Volume SMA 20: 19247818.38 (increasing)
- On-Balance Volume (OBV): 168035788.81 (strong bullish momentum)
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines highlight regulatory issues, earnings misses, and acquisition rumors.
Sentiment Assessment: Overall sentiment is neutral, with a mix of positive and negative headlines.
Catalyst Identification: Upcoming events include Sun Pharma's acquisition of Organon, which may impact OGN's price movement.
Market Narrative: The market narrative is mixed, with some headlines supporting the company's growth while others highlight potential risks.
Risk & Volatility Assessment
Beta Interpretation: Beta (1.06) indicates above-average volatility relative to the broader market.
Volatility Regime: Current volatility levels are high, exceeding historical averages.
Options Market Signals:
- IV rank: 17.9% (Low)
- Put/call volume ratio: 0.19 (Bullish sentiment)
Market Context & Positioning
Sector Performance: Organon is outperforming its sector peers.
Institutional Activity: Institutional interest in OGN is moderate, with increasing volume and a strong OBV signal.
Correlation Analysis: OGN has a moderate correlation coefficient (0.18) with the broader market.
Relative Valuation: OGN's current price relative to its trading range suggests it may be due for a correction or pullback.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $5.63
- Middle MA (SMA 20): $10.36
Breakout/Breakdown Levels: Monitor the upper and lower Bollinger Bands for potential price movements.
Time-Sensitive Catalysts: Sun Pharma's acquisition of Organon may impact OGN's price movement in the near term.
Risk Management: Consider placing stop-loss orders around the critical support levels to manage risk.
Generated
News
All OGN news →
Zacks Investment ResearchT3·20d ago
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·5mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
18 of 20 under expected move
Avg Expected Move
11.68%
Avg Actual Move
4.52%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-08-12 | After-Close | 7.25% | 2.12% | 0.29x | Within |
| 2021-11-12 | After-Close | 5.79% | 0.95% | 0.16x | Within |
| 2022-02-17 | After-Close | 3.99% | 0.77% | 0.19x | Within |
| 2022-05-05 | After-Close | 5.74% | 0.29% | 0.05x | Within |
| 2022-08-04 | After-Close | 9.69% | 2.81% | 0.29x | Within |
| 2022-11-03 | After-Close | 6.22% | 5.91% | 0.95x | Within |
| 2023-02-16 | After-Close | 6.35% | 4.62% | 0.73x | Within |
| 2023-05-04 | After-Close | 6.27% | 2.32% | 0.37x | Within |
| 2023-08-08 | After-Close | 6.94% | 2.57% | 0.37x | Within |
| 2023-11-02 | After-Close | 9.99% | 1.45% | 0.15x | Within |
| 2024-02-15 | After-Close | 6.77% | 0.48% | 0.07x | Within |
| 2024-05-02 | After-Close | 6.67% | 0.56% | 0.08x | Within |
| 2024-08-06 | Pre-Market | 9.91% | 7.63% | 0.77x | Within |
| 2024-10-31 | After-Close | 9.32% | 3.78% | 0.41x | Within |
| 2025-02-13 | After-Close | 8.12% | 6.37% | 0.78x | Within |
| 2025-05-01 | Pre-Market | 12.76% | 26.91% | 2.11x | Exceeded |
| 2025-08-05 | Pre-Market | 10.34% | 13.13% | 1.27x | Exceeded |
| 2025-11-10 | After-Close | 11.35% | 2.46% | 0.22x | Within |
| 2026-02-12 | After-Close | 12.39% | 4.67% | 0.38x | Within |
| 2026-04-30 | Pre-Market | 77.77% | 0.67% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
OGN Options Activity & IV Rank
OGN IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 35.7%
7-DTE IV: —
Expected Move: $11.20
7-DTE Move: $11.20
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 44
Put Volume: 14
P/C Volume: 0.318
BULLISH
Call OI: 58
Put OI: 8
P/C OI: 0.138
Total OI: 66
ATM Options Pricing
ATM Call: $10.00
ATM Put: $1.20
Call %: 72.7%
Put %: 8.7%
Chain Summary
Chain Volume: 2,635
Chain OI: 80,777
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 97th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
97%
vs own history
GEX tilt
+0.92
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 5 ATM contracts, 5k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 22 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 22 · ATM 61.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)27.2MediumOct 22
Straddle Price (30 DTE)$11.20Oct 22
Beta Analysis
Risk Metrics
Beta: 0.6194
Alpha: 54.29%
Correlation: 0.1212
R-Squared: 1.5%
Stock Volatility: 65.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
OGN Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 263,690,500 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
23 filers$63.76M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $19.64M | 30.81% | 2026-06-30 |
| 2 | Balyasny Asset Management L.P. | $8.12M | 12.74% | 2026-06-30 |
| 3 | Lombard Odier Asset Management (USA) Corp | $7.11M | 11.15% | 2026-06-30 |
| 4 | Verition Fund Management LLC | $6.47M | 10.15% | 2026-06-30 |
| 5 | Parallax Volatility Advisers, L.P. | $3.45M | 5.42% | 2026-06-30 |
| 6 | BOOTHBAY FUND MANAGEMENT, LLC | $3.31M | 5.19% | 2026-06-30 |
| 7 | Jane Street Group, LLC Custodian | $2.41M | 3.78% | 2026-06-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $2.25M | 3.53% | 2026-06-30 |
| 9 | Citadel Advisors LLC Custodian | $2.20M | 3.46% | 2026-06-30 |
| 10 | IMC-Chicago, LLC Custodian | $1.91M | 3.00% | 2026-06-30 |
| 11 | Wolverine Trading, LLC Custodian | $1.43M | 2.24% | 2025-09-30 |
| 12 | CAPITAL FUND MANAGEMENT S.A. | $1.17M | 1.84% | 2026-06-30 |
| 13 | Walleye Capital LLC | $1.12M | 1.76% | 2026-06-30 |
| 14 | Simplex Trading, LLC Custodian | $668.88K | 1.05% | 2026-06-30 |
| 15 | Walleye Trading LLC | $660.75K | 1.04% | 2026-06-30 |
| 16 | Decagon Asset Management LLP | $618.78K | 0.97% | 2026-06-30 |
| 17 | Cubist Systematic Strategies, LLC | $419.72K | 0.66% | 2025-09-30 |
| 18 | Centiva Capital, LP | $276.22K | 0.43% | 2026-06-30 |
| 19 | D. E. Shaw & Co., Inc. Custodian | $238.30K | 0.37% | 2026-06-30 |
| 20 | Meteora Capital, LLC | $106.80K | 0.17% | 2026-06-30 |
| 21 | KLCM Advisors, Inc. | $94.78K | 0.15% | 2026-06-30 |
| 22 | CSS LLC/IL | $67.70K | 0.11% | 2026-06-30 |
| 23 | Raiffeisen Bank International AG | $271 | <0.01% | 2026-06-30 |
21 filers$77.27M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Parallax Volatility Advisers, L.P. | $21.69M | 28.07% | 2026-06-30 |
| 2 | WATER ISLAND CAPITAL LLC | $13.19M | 17.07% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $11.17M | 14.46% | 2026-06-30 |
| 4 | Balyasny Asset Management L.P. | $6.77M | 8.76% | 2026-06-30 |
| 5 | Schonfeld Strategic Advisors LLC | $6.77M | 8.76% | 2026-06-30 |
| 6 | Citadel Advisors LLC Custodian | $4.60M | 5.95% | 2026-06-30 |
| 7 | Centiva Capital, LP | $3.38M | 4.38% | 2026-06-30 |
| 8 | IMC-Chicago, LLC Custodian | $1.98M | 2.56% | 2026-06-30 |
| 9 | Jane Street Group, LLC Custodian | $1.75M | 2.27% | 2026-06-30 |
| 10 | Simplex Trading, LLC Custodian | $1.38M | 1.78% | 2026-06-30 |
| 11 | CAPITAL FUND MANAGEMENT S.A. | $1.14M | 1.48% | 2026-06-30 |
| 12 | Wolverine Trading, LLC Custodian | $869.40K | 1.13% | 2025-09-30 |
| 13 | WOLVERINE ASSET MANAGEMENT LLC | $732.51K | 0.95% | 2026-06-30 |
| 14 | Lombard Odier Asset Management (USA) Corp | $677.00K | 0.88% | 2026-06-30 |
| 15 | Cubist Systematic Strategies, LLC | $415.45K | 0.54% | 2025-09-30 |
| 16 | GROUP ONE TRADING LLC Custodian | $391.31K | 0.51% | 2026-06-30 |
| 17 | Walleye Capital LLC | $161.13K | 0.21% | 2026-06-30 |
| 18 | EQUITEC PROPRIETARY MARKETS, LLC | $120.51K | 0.16% | 2026-06-30 |
| 19 | SUMMIT SECURITIES GROUP LLC | $41.97K | 0.05% | 2026-06-30 |
| 20 | GLAZER CAPITAL, LLC | $29.00K | 0.04% | 2026-06-30 |
| 21 | PRELUDE CAPITAL MANAGEMENT, LLC | $2.81K | <0.01% | 2026-06-30 |
OGN Insider Trading (Form 4)
Latest: 2026-08-12Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-12 | Ferreira Juan Camilo Arjona | Head of R&D & CMO | Mixed | +7,385 | $13.62 | -$56.3K | EDGAR |
| 2026-08-05 | Juliana Papa Drinane | Head of Mfg & Supply | Sell (S) | −14,761 | $13.57 | -$200.3K | EDGAR |
| 2026-06-15 | Cynthia M Patton | Director | Grant (A) | +17,857 RSU | — | EDGAR | |
| 2026-06-15 | Shalini Sharp | Director | Grant (A) | +17,857 RSU | — | EDGAR | |
| 2026-06-15 | Rochelle B Lazarus | Director | Grant (A) | +17,857 RSU | — | EDGAR | |
| 2026-06-15 | Philip Ozuah | Director | Grant (A) | +17,857 RSU | — | EDGAR | |
| 2026-06-15 | Ramona Sequeira | Director | Grant (A) | +17,857 RSU | — | EDGAR | |
| 2026-06-15 | Helene D Gayle | Director | Grant (A) | +17,857 RSU | — | EDGAR | |
| 2026-06-15 | Deborah R Leone | Director | Grant (A) | +17,857 RSU | — | EDGAR | |
| 2026-06-15 | Robert Essner | Director | Grant (A) | +17,857 RSU | — | EDGAR | |
| 2026-06-15 | Alan Ezekowitz | Director | Grant (A) | +17,857 RSU | — | EDGAR | |
| 2026-05-07 | Lynette Holzbaur | SVP and Corporate Controller | Mixed | −26,402 | $13.35 | -$353.1K | EDGAR |
| 2026-05-07 | Lynette Holzbaur | SVP and Corporate Controller | Buy (P) | +26,448 | $13.35 | $353.1K | EDGAR |
| 2026-04-02 | Joseph T. Morrissey Jr. | Interim CEO | Mixed | +17,579 | $5.70 | -$39.9K | EDGAR |
| 2026-04-02 | Lynette Holzbaur | SVP and Corporate Controller | Mixed | +7,841 | $5.70 | -$17.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
OGN Insider Holdings
17 insiders · @ $13.75
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Kevin Ali | Chief Executive Officer | 282,731 | $3.89M | $299.4K | 18 | 2025-05-06 |
| 2 | Matthew M Walsh | Chief Financial Officer | 212,746 | $2.93M | $100.5K | 20 | 2026-04-02 |
| 3 | Joseph T. Morrissey Jr. | Interim CEO | 127,906 | $1.76M | $0 | 21 | 2026-04-02 |
| 4 | Rachel A Stahler | Chief Information Officer | 120,322 | $1.65M | $0 | 19 | 2026-04-02 |
| 5 | Aaron Falcione | Chief Human Resources Officer | 101,431 | $1.39M | $48.2K | 21 | 2026-04-02 |
| 6 | Kirke Weaver | Gen. Counsel & Corp. Secy. | 96,147 | $1.32M | $124.0K | 14 | 2026-04-02 |
| 7 | Carrie Smith Cox | Executive Chair | 90,338 | $1.24M | $602.3K | 7 | 2025-11-13 |
| 8 | Daniel Karp | Executive VP, Corp. Dev. | 71,652 | $985.2K | $28.8K | 4 | 2026-04-02 |
| 9 | Vittorio Nisita | Head of Global Business Svcs | 65,100 | $895.1K | $0 | 20 | 2026-04-02 |
| 10 | Lynette Holzbaur | SVP and Corporate Controller | 52,850 | $726.7K | $0 | 6 | 2026-05-07 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
OGN Board & Officers
As of SEC filings through Aug 12, 2026Directors 12
- Shalini Sharp · since May 14, 2021
- Alan Ezekowitz · since Jun 2, 2021
- Carrie Smith Cox · since Jun 2, 2021
- Cynthia M Patton · since Jun 2, 2021
- Deborah R Leone · since Jun 2, 2021
- Grace Puma Whiteford · since Jun 2, 2021
- Helene D Gayle · since Jun 2, 2021
- Philip Ozuah · since Jun 2, 2021
- Robert Essner · since Jun 2, 2021
- Rochelle B Lazarus · since Jun 2, 2021
- Kevin Ali · listed since Mar 2023
- Ramona Sequeira · since Jul 1, 2025
Officers 11
- Joseph T. Morrissey Jr. · Interim CEO · listed since Nov 2025
- Matthew M Walsh · Chief Financial Officer · since May 7, 2021
- Aaron Falcione · Chief Human Resources Officer · since Jun 2, 2021
- Rachel A Stahler · Chief Information Officer · since Jun 2, 2021
- Vittorio Nisita · Head of Global Business Svcs · since Jun 2, 2021
- Kirke Weaver · Gen. Counsel & Corp. Secy. · since Jan 1, 2023
- Ferreira Juan Camilo Arjona · Head of R&D & CMO · since Jan 1, 2024
- Daniel Karp · Executive VP, Corp. Dev. · since Sep 9, 2024
- Lynette Holzbaur · SVP and Corporate Controller · since May 15, 2025
- Juliana Papa Drinane · Interim Head of Mfg & Supply · since Oct 27, 2025
- Carrie Smith Cox · Executive Chair · listed since Nov 2025
Changes in the last 10 years (45)
| Nov 17, 2025 | Joseph T. Morrissey Jr. listed as Interim CEO (previously Head of Manufacturing) in SEC filings |
| Nov 13, 2025 | Carrie Smith Cox first listed as Executive Chair in an SEC filing |
| Oct 27, 2025 | Juliana Papa Drinane became Interim Head of Mfg & Supply |
| Jul 1, 2025 | Ramona Sequeira became a director |
| May 15, 2025 | Lynette Holzbaur became SVP and Corporate Controller |
| Jan 15, 2025 | The company announced the departure of Susanne Fiedler as Chief Commercial Officer in an SEC filing |
| Dec 4, 2024 | The company announced the departure of Martha E McGarry from the board in an SEC filing |
| Sep 9, 2024 | Daniel Karp became Executive VP, Corp. Dev. |
| Jan 1, 2024 | Ferreira Juan Camilo Arjona became Head of R&D & CMO |
| Dec 5, 2023 | The company announced the departure of Sandra Milligan as Head of Research & Development in an SEC filing |
| Mar 2, 2023 | Kevin Ali first listed as a director in an SEC filing |
| Mar 2, 2023 | Geralyn S Ritter listed as Head of Ext. Affairs and ESG (previously Hd of Ext. Affairs and ESG) in SEC filings |
| Jan 1, 2023 | Kirke Weaver became Gen. Counsel & Corp. Secy. |
| Jul 7, 2022 | The company announced the departure of Deborah H Telman as Gen Counsel & Corp Sec in an SEC filing |
| Apr 4, 2022 | Kevin Ali no longer listed as a director in SEC filings |
| Aug 19, 2021 | Deborah H Telman listed as Gen Counsel & Corp Sec (previously General Counsel) in SEC filings |
| Jun 4, 2021 | Merck & Co., Inc. reported in an SEC filing no longer being a 10% owner |
| Jun 4, 2021 | Kevin Ali first listed as a director in an SEC filing |
| Jun 2, 2021 | Vittorio Nisita became Head of Global Business Svcs |
| Jun 2, 2021 | Susanne Fiedler became Chief Commercial Officer |
| Jun 2, 2021 | Sandra Milligan became Head of Research & Development |
| Jun 2, 2021 | Rochelle B Lazarus became a director |
| Jun 2, 2021 | Robert Essner became a director |
| Jun 2, 2021 | Rachel A Stahler became Chief Information Officer |
| Jun 2, 2021 | Philip Ozuah became a director |
| Jun 2, 2021 | Martha E McGarry became a director |
| Jun 2, 2021 | Ma. Fatima Francisco became a director |
| Jun 2, 2021 | Kathryn DiMarco became Corporate Controller |
| Jun 2, 2021 | Joseph T. Morrissey Jr. became Head of Manufacturing |
| Jun 2, 2021 | Helene D Gayle became a director |
| Jun 2, 2021 | Grace Puma Whiteford became a director |
| Jun 2, 2021 | Geralyn S Ritter became Hd of Ext. Affairs and ESG |
| Jun 2, 2021 | Deborah R Leone became a director |
| Jun 2, 2021 | Deborah H Telman became General Counsel |
| Jun 2, 2021 | Cynthia M Patton became a director |
| Jun 2, 2021 | Carrie Smith Cox became a director |
| Jun 2, 2021 | Alan Ezekowitz became a director |
| Jun 2, 2021 | Aaron Falcione became Chief Human Resources Officer |
| May 14, 2021 | Shalini Sharp became a director |
| May 7, 2021 | Rita A Karachun became a director |
| May 7, 2021 | Merck & Co., Inc. became a 10% owner |
| May 7, 2021 | Matthew M Walsh became Chief Financial Officer |
| May 7, 2021 | Kevin Ali became Chief Executive Officer |
| May 7, 2021 | Jon Filderman became a director |
| May 7, 2021 | Caroline Litchfield became a director |
Not reported recently (6)
- Kathryn DiMarco · Last reported as Corporate Controller in an SEC filing dated Apr 2, 2025
- Ma. Fatima Francisco · Last reported as a director in an SEC filing dated Jun 13, 2023
- Geralyn S Ritter · Last reported as Head of Ext. Affairs and ESG in an SEC filing dated May 8, 2023
- Caroline Litchfield · Last reported as a director in an SEC filing dated May 7, 2021
- Rita A Karachun · Last reported as a director in an SEC filing dated May 7, 2021
- Jon Filderman · Last reported as a director in an SEC filing dated May 7, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
OGN Proposed Insider Sales (Form 144)
Latest: 2026-08-05
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $200K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
JULIANA P DRINANE (1, $200K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | JULIANA P DRINANE | Officer | 14,761 | $200.3K | 2026-08-05 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-08 | Holzbaur Lynette | Affiliate | 26,448 | $353.1K | 2026-05-06 | Morgan Stanley Global Stock Plan… | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-30 | 0001104659-26-052165 | EDGAR |
| 2026-04-27 | 0001193125-26-178718 | EDGAR |
| 2026-02-20 | 0001104659-26-017870 | EDGAR |
| 2026-02-12 | 0001104659-26-013888 | EDGAR |
| 2025-11-10 | 0001104659-25-108821 | EDGAR |
| 2025-11-07 | 0001104659-25-108130 | EDGAR |
| 2025-10-27 | 0001104659-25-102324 | EDGAR |
| 2025-08-05 | 0001104659-25-073929 | EDGAR |
| 2025-06-12 | 0001104659-25-058900 | EDGAR |
| 2025-05-27 | 0001104659-25-052994 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-04 | 0001628280-26-029532 | EDGAR |
| 2025-11-10 | 0001628280-25-050795 | EDGAR |
| 2025-08-06 | 0001821825-25-000066 | EDGAR |
| 2025-05-02 | 0001821825-25-000023 | EDGAR |
| 2024-11-01 | 0001821825-24-000108 | EDGAR |
| 2024-08-07 | 0001821825-24-000083 | EDGAR |
| 2024-05-03 | 0001821825-24-000056 | EDGAR |
| 2023-11-03 | 0001821825-23-000013 | EDGAR |
| 2023-08-09 | 0001821825-23-000010 | EDGAR |
| 2023-05-05 | 0001821825-23-000006 | EDGAR |
ETF Holders
114 ETFs hold OGN
25 shown · $766.80M total exposure · 0.13% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.21% | $215.0M | $103.8B | 2026-10-21 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $114.8M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.05% | $80.9M | — | 2026-09-30 |
| 4 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.08% | $52.7M | — | 2026-09-30 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.04% | $40.5M | — | 2026-09-30 |
| 6 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.21% | $33.0M | $15.8B | 2026-10-21 |
| 7 | IJS iShares S&P Small-Cap 600 Value ETF | iShares (BlackRock) | 0.40% | $30.0M | $7.7B | 2026-10-21 |
| 8 | SLYV State Street® SPDR® S&P 600™ Small Cap Value ETF | SPDR (State Street) | 0.40% | $18.8M | $4.7B | 2026-10-21 |
| 9 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.07% | $16.7M | — | 2026-05-31 |
| 10 | BSJS Invesco BulletShares 2028 High Yield Corporate Bond ETF | Invesco | 2.08% | $15.9M | — | 2026-10-21 |
| 11 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.03% | $15.2M | $57.2B | 2026-10-21 |
| 12 | VYM Vanguard High Dividend Yield ETF | Vanguard | 0.02% | $14.6M | — | 2026-09-30 |
| 13 | FNDX Schwab Fundamental U.S. Large Company ETF | Nport | 0.05% | $13.8M | — | 2026-05-31 |
| 14 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.21% | $12.7M | — | 2026-09-30 |
| 15 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.79% | $12.2M | $1.6B | 2026-10-21 |
| 16 | VHT Vanguard Health Care ETF | Vanguard | 0.05% | $11.0M | — | 2026-09-30 |
| 17 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.03% | $10.1M | — | 2026-10-21 |
| 18 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 2.03% | $9.2M | $450.9M | 2026-10-21 |
| 19 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.01% | $8.0M | $84.8B | 2026-10-21 |
| 20 | RWJ Invesco S&P SmallCap 600 Revenue ETF | Invesco | 0.40% | $7.9M | — | 2026-10-21 |
| 21 | VIOV Vanguard S&P Small-Cap 600 Value ETF | Vanguard | 0.40% | $7.4M | — | 2026-09-30 |
| 22 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.22% | $6.9M | $3.1B | 2026-10-21 |
| 23 | MNA NYLIM Merger Arbitrage ETF | Nport | 2.71% | $6.8M | — | 2026-07-31 |
| 24 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.09% | $6.8M | — | 2026-10-21 |
| 25 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.83% | $6.0M | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
17.63
TTM Diluted EPS
$0.78
TTM Revenue
$6.13B
TTM Net Income
$209.00M
TTM Op. Cash Flow
$737.00M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $1.56B | $108.00M | $0.40 | $107.00M |
| Q1 '26 | 2026-03-31 | $1.46B | $146.00M | $0.55 | $225.00M |
| Q4 '25 | 2025-12-31 | $1.51B | $-205.00M | $-0.78 | $141.00M |
| Q3 '25 | 2025-09-30 | $1.60B | $160.00M | $0.61 | $264.00M |
| Q2 '25 | 2025-06-30 | $1.59B | $145.00M | $0.56 | $220.00M |
| Q1 '25 | 2025-03-31 | $1.51B | $87.00M | $0.33 | $75.00M |
| Q4 '24 | 2024-12-31 | $1.59B | $109.00M | $0.41 | $390.00M |
| Q3 '24 | 2024-09-30 | $1.58B | $359.00M | $1.38 | $141.00M |
| Q2 '24 | 2024-06-30 | $1.61B | $195.00M | $0.75 | $332.00M |
| Q1 '24 | 2024-03-31 | $1.62B | $201.00M | $0.78 | $76.00M |
| Q4 '23 | 2023-12-31 | $1.60B | $546.00M | $2.13 | $397.00M |
| Q3 '23 | 2023-09-30 | $1.52B | $58.00M | $0.23 | $261.00M |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-31
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
17.63
P/B
3.60
P/S
0.59
EV/EBITDA
7.23
EV/Sales
1.79
ROE
20.8%
ROA
1.6%
Div Yield
0.50%
FCF Yield
20.33%
Debt/Equity
8.43
Current Ratio
—
Market Cap
$3.63B
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
18.96M
SI % of Float
7.25%
Days to Cover
9.05
Short Vol Ratio
50.8%
Free Float
261.48M
Float %
99.6%
Short interest 2026-09-30 • Short volume 2026-10-22 • Float 2026-08-24